Clinic-controlled purchasing
Supplier identity and origin remain connected to the clinic's own procurement trail.
Peptide quality · Buyer intelligence
How to evaluate peptide quality, identity, COA and traceability.
A practical quality framework for people buying peptides online or entering a medical pathway: exact identity, batch-specific testing, provenance, storage and accountability.
For people evaluating peptide quality before buying online or entering a medically supervised pathway.Inspect the COA verification library →
Peptide quality · evidence you can interrogate
A COA is a claim until it matches the exact product in front of you.
The useful question is not whether a PDF exists, but whether identity, lot, laboratory, method, date and measured result resolve to the proposed supply.
Presentation- and lot-specific verification- Identity
- Molecule, formulation, strength and presentation must match.
- Lot
- The analytical record must resolve to the current proposed lot, not a previous or neighbouring batch.
- Laboratory
- Name, method, date, measured result and document provenance must be inspectable.
- What a COA proves
- Only the analytes and properties actually measured by the stated method.
- What it does not prove
- Sterility, endotoxin, clinical efficacy, lawful access or another product unless those matters are separately evidenced.
- Release decision
- Receipt, storage, product match and current documentation are checked before a pathway is represented as traced.
Procurement dossier · Evidence boundaries
A purchase record, a COA and a supplied vial answer different questions.
- Supplier and origin: the dossier documents a July 2026 purchase by PT Cepat Sehat Bali from Lumo Medicals Co., Ltd., Republic of Korea.
- Transaction: invoice and bank-transfer records support the commercial relationship. They do not establish molecular identity or purity.
- Analytical records: supplied records for named NAD+, tirzepatide and retatrutide presentations report RP-HPLC with UV detection for identity and quantity; some also report purity.
- Critical boundary: those records cannot be transferred to a different molecule, presentation or lot. BPC-157 and every patient-facing supply require their own matching documentation check.
- Clinical release: receipt, storage, current availability and the documentation attached to the proposed supply are confirmed before a final clinical pathway is represented as traced.
Product-to-patient trace
Traceability preserves scientific attribution.
A certificate does not prove efficacy. It helps establish which entity and batch entered the clinical record so that subsequent observations remain attributable.
Identity and analytical record
Lot reference and COA preserve the relationship between the proposed molecule and the supplied preparation.
Receipt, storage and preparation
Documented handling protects the continuity between analytical identity and the administered product.
Protocol and longitudinal response
The exact batch, route, dose, tolerance and response enter one clinical trajectory.
Clinic Terrain controls the purchase
Clinic Terrain purchases peptide presentations through its documented procurement route. The purchasing record anchors the named supplier, Korean origin, ordered presentation and transaction; it does not by itself prove molecular identity or purity.
The analytical record must match the product
A useful COA resolves to the exact molecule, presentation and lot and states the laboratory, method, date and measured result. Clinic Terrain connects each published analytical record only to the presentation tested and requires a current-lot match in the product-release decision.
Storage remains part of provenance
Receipt and storage information extend the product trail beyond the purchase. Documentation remains useful only when identity and handling stay connected throughout the clinic’s supply path.
The physician connects product to person
The clinical objective, relevant history, medication and baseline information shape the protocol. Product traceability and medical judgement remain visible as two connected parts of the same route.
Follow-up completes the chain
Batch, protocol, adherence, symptoms, measurements and response enter the longitudinal patient record. The next consultation can therefore use the precise product trail and the patient’s actual trajectory.
Current analytical set · independently retrievable
Four real records, separated by molecule and presentation.
Each QR and direct certificate link resolves to the named Chromate job. Clinic Terrain owns the separate product-release decision for the current presentation and lot.
QR VERIFIEDNAD+ analytical reference · exact product match required
NAD+
500mg · clear liquid
- Laboratory record
- Chromate job 27740
- Measured
- 532.9mg reported · purity not reported
- Method
- RP-HPLC with UV detection
- Analysis date
- 5 September 2025
This record reports identity and quantity for the tested 500mg liquid presentation. Purity is not included; the product proposed for use requires its own matching current documentation.
QR VERIFIEDNAD+ analytical reference · identity, quantity and purity
NAD+
500mg · lyophilised vial
- Laboratory record
- Chromate job 31392
- Measured
- 487.4mg reported · 99.724% reported
- Method
- RP-HPLC with UV detection
- Analysis date
- 20 January 2026
This record reports identity, quantity and purity for the tested 500mg lyophilised presentation. The product proposed for use requires matching current documentation.
QR VERIFIEDTirzepatide analytical reference · presentation-specific
Tirzepatide
15mg · lyophilised vial
- Laboratory record
- Chromate job 28437
- Measured
- 15.65mg reported · 99.896% reported
- Method
- RP-HPLC with UV detection
- Analysis date
- 8 October 2025
This record applies to the tested 15mg lyophilised presentation. A different dose, format or product requires its own matching current documentation.
QR VERIFIEDRetatrutide analytical reference · presentation-specific
Retatrutide
30mg · clear liquid
- Laboratory record
- Chromate job 36517
- Measured
- 31.81mg reported · 98.430% reported
- Method
- RP-HPLC with UV detection
- Analysis date
- 25 June 2026
This record applies to the tested 30mg liquid presentation. A different dose, format or product requires its own matching current documentation.
Connected clinical library
Peptides, selected for a person and traced to a product.
Molecule-specific expertise, physician selection, controlled sourcing, presentation-specific document matching and longitudinal follow-up.
Direct answers
Questions that expose a weak product trail.
Where do Clinic Terrain peptides come from?
Clinic Terrain sources and purchases its peptide supply directly from South Korea.
Is a COA retained?
Where a batch-specific analytical record exists, it is assessed against the molecule, presentation and lot. The clinic does not treat a generic supplier certificate or a record for another product as proof for the proposed supply.
What does the patient record connect?
It connects objective, clinical context, batch, protocol and follow-up so the next decision starts from a documented product and response history.
Evidence position
Korean origin, supplier identity, purchase record, receipt and storage information support distinct parts of the product trail. Any analytical record must match the exact molecule, presentation and lot before it can support an identity or quantity claim.
Sources used for this page
Regulatory guidanceWHO: good storage and distribution practices for medical products ↗International principles for documented purchasing, receipt, storage, distribution and supply-chain integrity.Regulatory guidanceICH: harmonised pharmaceutical quality guidelines ↗Quality frameworks covering analytical validation, specifications, stability, manufacturing and pharmaceutical quality systems.Your first message · Where you are + what you need help with